IL139950A0 - Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means - Google Patents
Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching meansInfo
- Publication number
- IL139950A0 IL139950A0 IL13995099A IL13995099A IL139950A0 IL 139950 A0 IL139950 A0 IL 139950A0 IL 13995099 A IL13995099 A IL 13995099A IL 13995099 A IL13995099 A IL 13995099A IL 139950 A0 IL139950 A0 IL 139950A0
- Authority
- IL
- Israel
- Prior art keywords
- cell
- target cell
- molecule
- complex
- hla class
- Prior art date
Links
- 230000002708 enhancing effect Effects 0.000 title abstract 2
- 230000005867 T cell response Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 6
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000003211 malignant effect Effects 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000009089 cytolysis Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9812227.8A GB9812227D0 (en) | 1998-06-05 | 1998-06-05 | Novel method |
| GB9908333A GB2339782A (en) | 1998-06-05 | 1999-04-12 | Chimeric protein complexes comprising HLA class I antigens |
| PCT/GB1999/001764 WO1999064464A2 (en) | 1998-06-05 | 1999-06-04 | Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL139950A0 true IL139950A0 (en) | 2002-02-10 |
Family
ID=26313811
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13995099A IL139950A0 (en) | 1998-06-05 | 1999-06-04 | Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means |
| IL139950A IL139950A (en) | 1998-06-05 | 2000-11-28 | Complex comprising an hla class i molecule or fragment thereof, presenting peptide for t cell recognition, stably bridged via small molecules |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL139950A IL139950A (en) | 1998-06-05 | 2000-11-28 | Complex comprising an hla class i molecule or fragment thereof, presenting peptide for t cell recognition, stably bridged via small molecules |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7268219B1 (de) |
| EP (1) | EP1093465B1 (de) |
| JP (1) | JP4587566B2 (de) |
| AT (1) | ATE372350T1 (de) |
| AU (1) | AU770596B2 (de) |
| CA (1) | CA2332642C (de) |
| CY (1) | CY1106948T1 (de) |
| DE (1) | DE69937055T2 (de) |
| DK (1) | DK1093465T3 (de) |
| ES (1) | ES2292259T3 (de) |
| GB (2) | GB2339782A (de) |
| IL (2) | IL139950A0 (de) |
| PT (1) | PT1093465E (de) |
| WO (1) | WO1999064464A2 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2339782A (en) | 1998-06-05 | 2000-02-09 | Philip Michael Savage | Chimeric protein complexes comprising HLA class I antigens |
| US7264965B2 (en) | 1998-06-05 | 2007-09-04 | Alexis Biotech Limited | Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means |
| US7521197B2 (en) | 1998-06-05 | 2009-04-21 | Alexis Biotech Limited | Method for producing cytotoxic T-cells |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| WO2001090198A1 (en) * | 2000-05-24 | 2001-11-29 | Ludwig Institute For Cancer Research | Multicomponent conjugates which bind to target molecules and stimulate cell lysis |
| US8022190B2 (en) | 2001-06-19 | 2011-09-20 | Technion Research & Development Foundation Ltd. | Immuno-molecules containing viral proteins, compositions thereof and methods of using |
| US20030017134A1 (en) * | 2001-06-19 | 2003-01-23 | Technion Research And Development Foundation Ltd. | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| GB2408507B (en) * | 2003-10-06 | 2005-12-14 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof for specific targeting |
| GB0426903D0 (en) * | 2004-12-08 | 2005-01-12 | Alexis Biotech Ltd | Complexes and methods |
| ES2549128T3 (es) | 2006-05-19 | 2015-10-23 | Technion Research And Development Foundation Ltd. | Proteínas de fusión, usos de las mismas y procesos para producir las mismas |
| CA2678618C (en) | 2007-02-21 | 2019-03-12 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cd1d molecules |
| AU2010203451B2 (en) | 2009-01-08 | 2016-06-30 | Albert Einstein College Of Medicine, Inc. | Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof |
| US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
| CN106282237A (zh) * | 2015-05-27 | 2017-01-04 | 北京大学 | 一种biotin-avidin-慢病毒表达载体和CAR-T细胞制备方法及可视化方案 |
| GB201609380D0 (en) * | 2016-05-27 | 2016-07-13 | Savage Philip M | HLA Targeting |
| US10294454B2 (en) | 2016-08-24 | 2019-05-21 | General Electric Company | Methods and kits for cell activation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3825615A1 (de) * | 1988-07-28 | 1990-02-01 | Behringwerke Ag | Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung |
| US5026785A (en) * | 1989-05-12 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Avidin and streptavidin modified water-soluble polymers such as polyacrylamide, and the use thereof in the construction of soluble multivalent macromolecular conjugates |
| AU3220593A (en) * | 1991-11-19 | 1993-06-15 | Anergen, Inc. | Soluble mhc molecules and their uses |
| DK0776339T4 (da) * | 1994-07-29 | 2010-05-25 | Sunol Molecular Corp | MHC-komplekser og anvendelser deraf |
| EP0870040A2 (de) * | 1995-12-29 | 1998-10-14 | Chiron Corporation | Genabgabevehikel-zielgerichtete ligande |
| US5869270A (en) * | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| EP0889964A1 (de) * | 1996-03-28 | 1999-01-13 | The Johns Hopkins University | Lösliche divalente und multivalente heterodimäre proteinanalogen |
| US6268411B1 (en) * | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
| US6248564B1 (en) * | 1997-08-29 | 2001-06-19 | Harvard University | Mutant MHC class I molecules |
| GB2339782A (en) | 1998-06-05 | 2000-02-09 | Philip Michael Savage | Chimeric protein complexes comprising HLA class I antigens |
-
1999
- 1999-04-12 GB GB9908333A patent/GB2339782A/en not_active Withdrawn
- 1999-06-04 DE DE69937055T patent/DE69937055T2/de not_active Expired - Lifetime
- 1999-06-04 CA CA002332642A patent/CA2332642C/en not_active Expired - Fee Related
- 1999-06-04 ES ES99955483T patent/ES2292259T3/es not_active Expired - Lifetime
- 1999-06-04 WO PCT/GB1999/001764 patent/WO1999064464A2/en active IP Right Grant
- 1999-06-04 AT AT99955483T patent/ATE372350T1/de not_active IP Right Cessation
- 1999-06-04 PT PT99955483T patent/PT1093465E/pt unknown
- 1999-06-04 GB GB0029565A patent/GB2355983B/en not_active Expired - Fee Related
- 1999-06-04 DK DK99955483T patent/DK1093465T3/da active
- 1999-06-04 EP EP99955483A patent/EP1093465B1/de not_active Expired - Lifetime
- 1999-06-04 AU AU42767/99A patent/AU770596B2/en not_active Ceased
- 1999-06-04 IL IL13995099A patent/IL139950A0/xx unknown
- 1999-06-04 JP JP2000553470A patent/JP4587566B2/ja not_active Expired - Fee Related
-
2000
- 2000-11-28 IL IL139950A patent/IL139950A/en not_active IP Right Cessation
- 2000-11-28 US US09/724,985 patent/US7268219B1/en not_active Expired - Fee Related
-
2007
- 2007-10-22 CY CY20071101357T patent/CY1106948T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1093465T3 (da) | 2008-01-07 |
| GB2355983A (en) | 2001-05-09 |
| US7268219B1 (en) | 2007-09-11 |
| EP1093465A2 (de) | 2001-04-25 |
| IL139950A (en) | 2009-06-15 |
| PT1093465E (pt) | 2007-09-24 |
| AU770596B2 (en) | 2004-02-26 |
| AU4276799A (en) | 1999-12-30 |
| CA2332642A1 (en) | 1999-12-16 |
| GB2339782A (en) | 2000-02-09 |
| CY1106948T1 (el) | 2012-09-26 |
| WO1999064464A2 (en) | 1999-12-16 |
| GB2355983B (en) | 2002-08-14 |
| EP1093465B1 (de) | 2007-09-05 |
| DE69937055T2 (de) | 2008-05-29 |
| JP2002517517A (ja) | 2002-06-18 |
| JP4587566B2 (ja) | 2010-11-24 |
| DE69937055D1 (de) | 2007-10-18 |
| ATE372350T1 (de) | 2007-09-15 |
| GB0029565D0 (en) | 2001-01-17 |
| ES2292259T3 (es) | 2008-03-01 |
| GB9908333D0 (en) | 1999-06-09 |
| CA2332642C (en) | 2010-01-05 |
| WO1999064464A3 (en) | 2000-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2355983B (en) | Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means | |
| AU2001288863A1 (en) | Compositions and methods for inducing specific cytolytic t cell responses | |
| CY1107628T1 (el) | Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων | |
| EP1434596A4 (de) | Verwendung von 4-1bb bindenden agenzien zur erhöhung der immunantwort | |
| HK1062029A1 (en) | Multiplication of viruses in a cell culture | |
| ATE315405T1 (de) | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung | |
| NL300307I1 (nl) | Werkwijzen voor de replicatie van influenzavirussen in celkweek en de influenzavirussen die verkrijgbaar zijn met behulp van de werkwijze | |
| AU2001235006A1 (en) | Prophylactic and therapeutic monoclonal antibodies | |
| WO2002036790A3 (en) | Influenza virus vector for infection of dendritic cells | |
| DE69934426D1 (de) | KREBSIMMUNTHERAPIE UND KREBSDIAGNOSE UNTER VERWENDUNG UNIVERSELLER TUMORASSOZIIERTER ANTIGENE EINSCHLIESSLICH hTERT | |
| WO2000000156A3 (en) | Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands | |
| HK1017905A1 (en) | Induction of T cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways. | |
| DE69734974D1 (de) | Verfahren zur transformation dendritischer zellen und aktivierung von t zellen | |
| BR9814432A (pt) | Composições derivadas de mycobacterium vaccae e processo para seu uso | |
| CA2232344A1 (en) | Compositions and methods for enhancing immune responses mediated by antigen-presenting cells | |
| UY26266A1 (es) | Antigeno asociado con tumores (r11) ley 17164 | |
| Riddell et al. | Immunotherapy of human viral and malignant diseases with genetically modified T-cell clones. | |
| DK1301637T3 (da) | DNA-vacciner, der koder for HIV accessoriske proteiner | |
| ATE248914T1 (de) | Allogenes vakzin und synthesemethode für selbiges | |
| DK0854727T3 (da) | Tumorafstødelsesantigener, der præsenteres af HLA-B44-molekyler, og anvendelser af samme | |
| ATE318300T1 (de) | Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe | |
| FR2856598A1 (fr) | Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale | |
| CY1108543T1 (el) | Εμβολια dna που κωδικοποιουν βοηθητικες πρωτεϊνες του hiv | |
| MX9606317A (es) | Metodos para la activacion de celulas t in vivo por celulas dentriticas impulsadas por antigenos. | |
| AU2003269060A1 (en) | Specific isotype antibodies of secretion-excretion anti-antigens of less thanigreater thanleishmania spless than/igreater than of promastigoteless thanigreater than less than/igreater thanor amastigote forms used as protection, resistance and curing markers of mammals to leishmaniases and to intracellular pathogenic micro-organism infections, and as immunotherapeutic effectors |